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Abstract
Background: Increased tryptophan metabolism towards the production of kynurenine via indoleamine/tryptophan-
2,3-dioxygenases (DOs: Ido1, Ido2, and Tdo2) is strongly associated with the prevalence of major depressive
disorder in patients and the induction of depression-like behaviors in animal models. Several studies have
suggested that activation of the immune system or elevated corticosteroids drive DO expression; however,
mechanisms linking cytokines, corticosteroids, and DOs to psychiatric diseases remain unclear. Various attempts
have been made to correlate DO gene expression within the brain to behavior, but disparate results have been
obtained. We believe that discrepancies arise as a result of the under-recognized existence of multiple mRNA
transcripts for each DO. Unfortunately, there are no reports regarding how the multiple transcripts are distributed or
regulated. Here, we used organotypic hippocampal slice cultures (OHSCs) to directly test the ability of inflammatory
and stress mediators to differentially regulate DO transcripts.
Methods: OHSCs were treated with pro-inflammatory mediators (interferon-gamma (IFNγ), lipopolysaccharide (LPS),
and polyinosine-polycytidylic acid (pI:C)) with or without corticosteroids (dexamethasone (Dex: glucocorticoid
receptor (GR) agonist), aldosterone (Aldo: mineralocorticoid receptor (MR) agonist), or corticosterone (Cort: GR/MR
agonist)).
Results: IFNγ induced Ido1-full length (FL) and Ido1-variant (v) expression, and surprisingly, Dex, Cort, and Aldo
interacted with IFNγ to further elevate expression of Ido1, importantly, in a transcript dependent manner. IFNγ, LPS,
and pI:C increased expression of Ido2-v1 and Ido2-v3 transcripts, whereas only IFNγ increased expression of Ido2-v2.
Overall Ido2 transcripts were relatively unaffected by GR or MR activation. Naïve mouse brain expresses multiple
Tdo2 transcripts. Dex and Cort induced expression of only one of the three Tdo2 transcripts (Tdo2-FL) in OHSCs.
Conclusions: These results establish that multiple transcripts for all three DOs are expressed within the mouse
hippocampus, under the control of distinct regulatory pathways. These data identify a previously unrecognized
interaction between corticosteroid receptor activation and inflammatory signals on DO gene expression, which
suggest that corticosteroids act to differentially enhance gene expression of Ido1, Ido2, and Tdo2.
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Background
The lifetime prevalence of major depressive disorder
(MDD) is almost 15 % [1] with nearly 10 % of the USA
population taking anti-depressants on any occasion [2].
Within the general population, prevalence is five to ten
times higher in patients with a known medical illness
[3], particularly when this medical illness is a chronic in-
flammatory condition [3]. For example, people with mul-
tiple sclerosis have a prevalence rate of MDD up to 50 %
[4]. Over the past 20 years, an association between the
immune system and MDD has been clearly established.
Studies have shown that patients with MDD have ele-
vated levels of immunomodulatory factors (pro-inflam-
matory cytokines) within the circulation and increased
expression of pro-inflammatory cytokines in the central
nervous system, neuroinflammation [5]. During chronic
administration of the pro-inflammatory cytokine IFNα
to patients with hepatitis C or malignant melanoma, up
to 45 % of patients eventually exhibit elevated symptoms
of MDD [6–8]. As such, patients who have undergone a
chronic immune challenge express a variety of depressive
symptoms [7, 9]. Now, one of the most pressing issues is
to determine how inflammatory cytokine signaling is
linked to a pathway responsible for depression-like
behaviors [10]. The answer to this question could aid in
development of new anti-depressant drugs that would
benefit a large percentage of the population. This is
especially pertinent considering that anti-depressants
are therapeutically effective in only 15 % of patients
after accounting for the placebo effect [11].
Several reports have identified polymorphisms associ-
ated with DO expression, an elevated immune response,
and dysregulation of the hypothalamic-pituitary-adrenal
axis. Polymorphisms in the Ido1 gene are associated
with both treatment efficiency of anti-depressants [12]
and symptomology of depression [13]. A polymorphism
in the promoter region of the Ido1 gene (rs9657182, CC
genotype) is a risk factor for patients to develop depres-
sion after immunotherapy [13]. An additional study [14]
found that patients are more likely to develop symptoms
of depression following immunotherapy if they harbored
the “high producer” allele (IFNγ + 874, T allele) that is
associated with elevated IFNγ expression [15, 16]. This
allele is also associated with increased DO activity [14, 17],
suggesting that this genotype may be a risk factor for in-
creased interferon/DO-induced depression [18]. There are
also functional polymorphisms in the GR gene associated
with symptoms of depression [19–21]. These data provide
accumulating evidence for convergence of immune
(IFNγ→DO) and stress (HPA dysregulation/corticoster-
oid→GR activation→DO expression) pathways involved
in depression. The least characterized aspect of this con-
vergence is the interaction between these two pathways as
regulatory pathways controlling DO expression.
Extensive research has illustrated mechanisms by which
inflammatory challenge induces a depression-like pheno-
type with rodent models. Administration of lipopolysac-
charide (LPS), polyinosine-polycytidylic acid (pI:C), or
infection with Mycobacterium bovis evokes peripheral and
CNS cytokine expression followed by the manifestation of
depression-like behaviors such as helplessness/despair
(increased immobility during tail suspension test, TST)
and anhedonia (decreased sucrose preference [22, 23].
Importantly, the development of depressive symptoms
is tied to elevated tryptophan metabolism to kynurenine
via the DOs [28] which are rate limiting for the metabolism
of tryptophan to kynurenine (Kyn) via the Kynurenine
Pathway [26–29]. Ido1, Ido2, and Tdo2 messenger RNA
(mRNA) expression are induced within the brain and per-
ipheral tissues by LPS and bacterial infection, pI:C and viral
infection, and systemic and CNS administration of
pro-inflammatory cytokines [25–28, 30–34]. Inflammatory
cytokines released during an immune challenge include
IFNγ, IFNα, interlukin-1 beta (IL-1ß), IL-6, and tumor ne-
crosis factor alpha (TNFα). These cytokines are necessary
to activate both lymphoid and myeloid cells in the
periphery and induce neuroinflammation, but their
presence is not sufficient to induce depression-like be-
haviors. DO induction is requisite for depressive-like behav-
iors as genetic knockout of Ido1 gene transcription (Ido1KO
mice) inhibits inflammation-dependent depression-like
behaviors [28, 29, 35]. Kyn produced by the DOs is not
directly responsible for behavioral changes. Kyn is further
metabolized by non-rate-limiting enzymes: kynureninase
(Kynu) + kynurenine 3-monooxygenase (KMO) leading to
quinolinic acid (QuinA) production or by kynurenine ami-
notransferase (Kat2) that generates kynurenine acid
(KynA) [36]. QuinA and KynA directly interact with neu-
rons to interfere with neurotransmitter activity, and they
are believed to be the end products responsible for the be-
havioral changes that are initiated and dependent on DO
expression. KynA acts on neurons to decrease glutamate
and acetylcholine signaling, whereas QuinA enhances
glutamate receptor activation on neurons, suggesting
that Kyn metabolites play distinct roles in the patho-
physiology and etiology of a variety of neurological
conditions [37, 38].
Similar to the effects of cytokines, a recent study has
shown that elevated corticosteroids increase Ido1 expres-
sion in the mouse hippocampus [39]. Chronic unpredict-
able mild stress increases both serum corticosterone and
Ido1 and leads to depression-like behaviors of rats [40].
Additionally, swimming stress is well known to elevate
blood corticosterone levels in mice, and when combined
with systemic LPS injection, there is an induction of Ido2
expression in the mouse hippocampus [32]. These data
suggest that inflammatory cytokines and stress hormones
can act both alone and together to induce Ido1 and Ido2
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expression. Although several papers indicate elevated
Tdo2 expression in the liver following corticosteroid ad-
ministration [41, 42], there are no studies investigating the
regulation of Tdo2 within the brain. Unfortunately, the
DO specificity, inflammatory-mediator specificity, and
corticosteroid-receptor specificity or their interactions
have not been defined.
Our first attempts to define the interaction between
inflammation and stress for the regulation of DO within
the brain were met with mixed results. Results differed
when we used quantitative PCR (qPCR) assays that amp-
lified the 5′ regions of the DOs versus qPCR assays that
amplified 3′ regions of the DOs. This discrepancy was
addressed by purchasing or designing qPCR assays that
specifically amplified the unique splice variants for each
DO (Fig. 1). Since both inflammatory stimuli and stress
hormones induce depression-like behaviors and DO up-
regulation, we hypothesized that inflammatory stimuli
and glucocorticoids interact to regulate DO expression.
More importantly, we hypothesized that splice variants
for the DO exist as a means to differentially regulate DO
expression dependent on the type of stimuli presented
to the brain. We found that both Dex and Cort (but not
Aldo) attenuate LPS and pI:C-induced pro-inflammatory
cytokine expression, a typical anti-inflammatory response.
Surprisingly, instead of diminishing the effect of in-
flammatory stimuli on Ido expression, corticosteroids
upregulated IFNγ-induced Ido1 expression in a transcript-
dependent manner. The corticosteroids had minimal
effects on Ido2 expression, but Ido2 was induced by both
LPS, pI:C and IFNγ, whereas Ido1 was only induced by
IFNγ. Only one of three Tdo2 transcripts was induced by
corticosteroids. These data uncover novel pathways that
can be manipulated to control DO expression.
Methods
Mice
C57BL/6J founders were purchased from Jackson La-
boratories. Pups were supplied from a breeding colony
established and maintained in the University of Illinois’s
Institute for Genomic Biology animal facility. All animal
care and use procedures were conducted in accordance
with the Guide for the Care and Use of Laboratory Animals
(National Research Council) and approved by the Institu-
tional Animal Care and Use Committee.
Reagents
Hank’s balanced salt solution (HBSS, SH30030.03),
heat-inactivated horse serum (SH30074.03), and MEM
(SH30024.02) were purchased from Hyclone (Logan, UT).
D-glucose (15023-021) was from Gibco (Carlsbad, CA).
Gey’s balanced salt solution (GBSS, G9779), pI:C (tested at
10 μg/ml, P0913), Dex (tested at 12.5 μM, D4902), Aldo
(tested at 100 nM, A9477), Cort (tested at 1 μM, 27840),
and LPS (tested at 2 μg/ml, Escherichia coli 0127:B8,
L-3129) were from Sigma (St. Louis, MO). Recombinant
mouse IFNγ (tested at 1 μg/ml, 315-05) was from
Peprotech (Minneapolis, MN). Since there are no publica-
tions describing the corticosteroid responsiveness or cor-
ticosteroid x inflammation interactions of organotypic
hippocampal slice cultures (OHSCs), we used treatment
doses to assure that consistent OHSC responses to both
types of stimuli were present.
Organotypic hippocampal slice cultures
OHSCs were prepared from 7- to 10-day old pups as
previously described [30]. Briefly, mice were decapitated
and brains were removed, followed by extraction of the
hippocampi from both brain hemispheres. Transverse
slices (350 μm) were prepared with a McIlwain tissue
chopper (Campden Instruments Ltd, UK) then transferred
onto porous (0.4 μm) transparent membrane inserts
(30 mm in diameter; EMD Millipore) with one slice from
each of six different mice per insert. Inserts were placed
into six-well culture plates with 1.25 ml of culture
medium composed of 25 % heat-inactivated horse serum,
25 % Hank’s Balanced Salt Solution (HBSS), 50 % Modi-
fied Eagle’s Medium (MEM), 1× penicillin/streptomycin
(Pen/Strep), 0.5 % D-glucose, and 15 mM 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid (HEPES buffer
pH 7.4). Plates were maintained in a humidified incubator
(5 % CO2, 95 % atmospheric air) at 37 °C. Medium was
changed every 2–3 days. On day 7 in culture after slices
had recovered from the inflammatory response associated
with slice preparation [30], OHSCs were rinsed several
times and incubated for 2 h in serum-free conditions
(Dulbecco’s MEM, Pen/Strep, HEPES, and 150 μg/ml bo-
vine serum albumin) before a replacement of the serum-
free medium and addition of treatments. Six hours follow-
ing addition of treatments, supernatants and tissues were
collected and stored at −80 °C for further analysis. A 6-h
treatment duration was chosen based on our finding that
the maximal cytokine and Ido1 mRNA responses to LPS
occurred after this duration [30].
Reverse transcription and real-time RT-PCR
Total RNA from OHSCs was extracted using a commer-
cially available kit as per the supplier’s instructions
(E.Z.N.A. Total RNA Kit II, Omega Bio-Tek, Norcross,
Georgia). RNA was reverse transcribed to complemen-
tary DNA (cDNA) using a high-capacity cDNA reverse
transcription kit (Applied Biosystems, Grand Island, NY).
The cDNA samples were analyzed for steady-state mRNA
levels (i.e., gene expression) by qPCR using TaqMan uni-
versal PCR master mix and the Prism 7900 thermocycler
(Applied Biosystems, Foster City, CA). Data were analyzed
using the comparative threshold cycle method (GAPDH
expression used to normalize target gene expression [27].
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Fig. 1 Gene, transcript, and qPCR assay information for murine Ido1, Ido2, and Tdo2. Top: Gene structure (to scale) is shown in the shaded areas
for each of the three DOs with each gene having either 11 or 12 exons. Ido1 and Ido2 are contiguous on chromosome 8, separated by only
7,733 bp (red bar). Tdo2 is located on chromosome 3. Each of the three genes are transcribed into multiple transcripts (exon inclusion for unique
transcripts are shown below the gene structure, approximate scale) which encode full-length (FL) and variant (v) forms of each protein (protein
coding areas shown in yellow within each transcript). Splicing patterns were taken from two databases (Ensemble and NCBI, neither of which
describe all of the variants) and two manuscripts [47, 48], all with unique naming criteria. Thus, simplified names for each transcript are used in
the manuscript (shown on the left, colored text) and database/manuscript sequence names are provided in black text. Ido2-v3 (Δ4 described in
[47]) is not listed in either database; a partial sequence of this transcript has been published (thick bar area), but when the transcript was
overexpressed, it encodes an active enzyme [47] that lacks 12 amino acids (due to the absence of the first 36 bp of exon 5). Invariant exons that are
used for all mRNA transcripts within DO are gray; exons that vary in usage or length are colored. Bottom: All qPCR assays were purchased from IDT.
User-specific (custom) assays were designed using the IDT PrimerQuest® Design Tool. It is not possible to design an assay specific to Tdo2-FL as its
complete sequence lies within Tdo2-v1 (however data within this manuscript indicate distinct differences in expression and regulation of Tdo2-FL and
Tdo2-v1). Ido2-v3:Δ4, Tdo2-FL/-v1/-v2 transcript names, and Tdo2 exon 0a and 0b exon designations are shown in the figure to agree with published
nomenclature [47]. Specifics shown for each qPCR assay include location (assay location is also shown in upper panel ), catalog numbers
(if predesigned by IDT), primer/probe sequences, and confirmed amplicon size
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Changes in target cDNA levels were analyzed by compar-
ing 2−ΔΔCts, where Ct is the cycle threshold.
DO transcripts and qPCR assay design
Much of this work was prompted by data generated
while investigating the mRNA expression of DOs across
mouse tissues. Results varied dependent on the qPCR
assay location. However, the average mouse gene has
three mRNA isoforms (seven for human) [43], suggest-
ing that a single qPCR assay may not detect the true ex-
pression level of a gene or intimacies of its tissue/
cellular distribution and regulation. To determine the
relevance of gene splicing to the DOs, it is important to
outline the multiple transcripts for the three DOs. The
gene structures and transcripts (two for Ido1, four for
Ido2, and three for Tdo2) are illustrated as are the qPCR
assays used to quantify each transcript (Fig. 1 bottom).
Correct amplicon size for each qPCR assay was con-
firmed by gel electrophoresis. Proteins transcribed from
these transcripts (~51 kDa Ido1-FL [24, 44], ~45 kDa
Ido1 (probably FL but possibly v1) [45, 46], ~54 kDa
Ido2-FL [24, 47], <54 kDa Ido2-v3 [47], ~46 kDa Tdo2-
FL [48], ~46 kDa Tdo2-v1 [48], and ~44 kDa Tdo2-v2
[48]) have been expressed and found to encode enzymat-
ically active proteins. Ido2-v1 and Ido2-v2 transcripts
are predicted to encode variant DO proteins that are dis-
tinct from the confirmed active Ido2-FL and Ido2-v3
encoded proteins (Fig. 1 top, Ensemble and NCBI data-
bases); enzymatic activity of these predicted proteins has
not been tested.
Cytokine levels
Media collected from slice cultures were analyzed for
TNFα and IL-6 levels using BD OptEIA™ ELISA kits
(BD Biosciences; San Diego, CA) following the manu-
facturer’s instructions.
Statistics
All data are presented as mean ± SEM. Gene expression
data are means of three to four independent OHSC
preparations. Two-way analysis of variance was performed
using SigmaPlot 13.0 software and a 2 × 6 arrangement of
treatments. Post hoc analysis for multiple comparisons
was performed only in the presence of a significant inter-
action, as assessed by Holm-Šídák method. Significance
was set at p ≤ 0.05 for all comparisons.
Results
Ido1, Ido2, and Tdo2 transcript expression differ between
tissues and across brain regions
Although gene expression has been published for several
of the DO transcripts, a quantitative comparison of full
length (FL) versus variant (v) transcripts has not been
performed for the three DOs within the brain or across
tissue types. Comparing brain regions to the lung and
liver, the Ido1-FL transcript is essentially absent (Ct values
≥37) in mouse brain (Fig. 2 top), but it is expressed in the
mouse liver and abundantly so in the lung. In contrast,
Ido1-v1 expression is lowest in liver but is expressed in
both the frontal cortex and hippocampus (Ct’s ~32) and is
again highest in the lung. The Ido2-FL transcript is lowest
in the mouse brain (Ct’s ~32), expressed in the lung, but
highest in the liver, essentially opposite of the expression
pattern for the Ido2-v1 transcript. Unlike either Ido1 or
Ido2, Tdo2 transcripts are lowest in the frontal cortex of
the mouse brain (Ct’s ~34), considerably higher in the
hippocampus and lung, but highest in the liver. These data
indicate that tissues differentially express specific tran-
scripts for each of the DOs. Thus, quantifying DO expres-
sion within different tissue may require the use of
different assays. These data also suggest that distinct
mechanisms must exist to determine which transcript will
be expressed. More importantly, these data indicate that a
single qPCR assay does not reflect changes in DO tran-
script levels. This is illustrated using assays that quantify
all transcript variants for each DO (-Tot). Total DO
mRNA expression does not realistically reflect relative ex-
pression of any given transcript, which is most obvious for
Ido2 where Ido2-v1 is highest in the frontal cortex
whereas Ido2-FL and Ido2-Tot are highest in the liver.
Given these major differences across tissues and two
brain regions, we analyzed additional brain regions for
the same DO transcripts. As shown in bottom of Fig. 2,
each region of the mouse brain has a distinct pattern of
DO expression. All brain regions from naïve mice have
essentially no Ido1-FL transcript expression (frontal cor-
tex average Ct = 38.9, see the figure for the average Ct
values of each transcript in the frontal cortex). All four
brain regions express varying levels of the other DO
transcripts. The frontal cortex is not particularly abun-
dant for any DO transcript; however, the hypothalamus
and striatum are enriched for Ido1-v1 and Ido2-FL ex-
pression, whereas the hippocampus and to a much
lesser extent the hypothalamus displays enriched Tdo2-FL
expression. Tdo2-v1 is similarly expressed across these
four brain regions. Ido1-Tot reflects Ido1-v1, because of
the absence of Ido1-FL. As such, a qPCR assay for Ido1-v1
or Ido1-Tot would not detect the essential absence of
Ido1-FL across these brain regions. Ido2-Tot reflects
Ido2-v1 because of the relatively high expression of the
variant compared Ido2-FL. Once again, note that assaying
brain regions with assays for Ido2-v1 or Ido2-Tot would
not detect the difference in relative abundance of Ido2-FL.
Tdo2-Tot expression reflects Tdo2-FL because of the
similar expression of the variant across brain regions.
Therefore, assaying brain regions with Tdo2-FL or Tdo2-
Tot assays would not detect the constant expression of
Tdo2-v1 across brain regions.
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Fig. 2 (See legend on next page.)
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The cause of the distribution differences noted above
is unknown, but it is clear that results will vary
dependent on the design of the qPCR assay. As a first
step to understand the differential regulation of DO ex-
pression, qPCR assays designed to quantify the various
DO transcripts (Fig. 1 bottom) were used to test for
differences in DO regulation in the hippocampus.
Given that Ido1 and Ido2 have previously been shown
to be induced by inflammatory signals, whereas Tdo2
is purportedly corticosteroid dependent, we next investi-
gated the individual and combined actions of inflamma-
tory mediators and corticosteroids on DO expression
using OHSCs.
Dex and Cort elicit expected anti-inflammatory and
negative feedback responses by OSHCs
We previously characterized the pro-inflammatory re-
sponsiveness of OHSCs by demonstrating that TNFα,
IL-6, and iNOS expression is induced by both LPS [30]
and IFNγ [49]. To confirm responsiveness of our slice
cultures to corticosteroids, we first tested for the widely
accepted anti-inflammatory role of corticosteroids and
the ability of corticosteroids to elicit a negative feedback
loop. The glucocorticoid receptor (GR) agonist dexametha-
sone (Dex), mineralocorticoid receptor (MR) agonist aldos-
terone (Aldo), or corticosterone (Cort; which binds to both
receptors with varying affinity; MR >GR) were tested in
the presence or absence of inflammatory mediators
(IFNγ, LPS, and pI:C). There was a significant inflamma-
tory mediator main effect on both TNFα and IL-6 mRNA
gene expression and protein secretion. IFNγ, LPS, and
pI:C induced TNFα, IL-6, and RANTES mRNA ex-
pression (Fig. 3a–c, respectively, p ≤ 0.01) as well as
TNFα and IL-6 protein secretion (insets). Dex significantly
(p < 0.001) decreased the ability of IFNγ, LPS, and pI:C to
induce cytokine/chemokine mRNA (Fig. 3a–c) and protein
expression (insets). Corticosterone had essentially the same
effect as Dex (not shown). Aldo did not affect cytokine or
chemokine expression or secretion (not shown). Interest-
ingly, Dex enhanced the ability of LPS and pI:C to induce
iNOS expression although Dex was ineffective when added
alone (Fig. 3d), indicating that signaling through the GR
can potentiate some inflammatory responses.
OHSCs express both the GR (Nr3c1) and MR (Nr3c2).
As expected, GR expression was decreased by Dex
(p < 0.001), a negative feedback response, but was un-
affected by inflammatory mediators (Fig. 3e). Cort mim-
icked this effect, whereas Aldo was inactive (not shown).
MR expression was unaffected by these treatments or
their combinations (Fig. 3f). These data indicate that GRs
are expressed and active as would be necessary for an
anti-inflammatory effect elicited by Dex or Cort, but not
Aldo. The lack of an anti-inflammatory effect of Aldo is
not due to the absence of the MR expression by OHSCs,
but an anti-inflammatory response was not expected by
MR activation. FK506 binding protein 5 (fkbp5; FKBP51)
and 4 (fkbp4; FKBP52) are considered regulators of cor-
ticosteroid receptor activity. FKBP51 acts as negative
regulator by preventing translocation of corticosteroid re-
ceptor complexes (CR:R) to the nucleus whereas FKBP52
serves as a positive regulator by binding to and translocat-
ing the CR:R complex to the nucleus to self-regulate their
activity primarily via the regulation of FKBP51 expression
[50]. To confirm that this pathway was intact in OHSCs,
we quantified FKBP51 and FKBP52 expression. Similar to
other reports, we found that Dex (Fig. 3g) increased ex-
pression of FKBP51 (p < 0.001). The Dex effect was dimin-
ished in the presence of LPS and pI:C. Cort, but not Aldo
(not shown), mimicked this response. Neither Dex
(Fig. 3h), Cort (not shown), Aldo (not shown), nor inflam-
matory mediators affected the expression of FKBP52.
Together, the data in Fig. 3 establish the ability of
corticosteroids to block or enhance specific inflammatory
responses (↓ cytokines, ↓ chemokine, and ↑ iNOS).
Corticosteroids also diminish (GR) or enhance (FKBP51)
expression of genes that are part of a negative feedback
regulation of corticosteroid action. Inflammatory media-
tors can attenuate corticosteroid action (↓ FKBP51). This
characterization is necessary to confirm that the OHSC
response is similar to those reported in both animal
(See figure on previous page.)
Fig. 2 Ido1, Ido2, and Tdo2 transcript expression differ between tissues and across brain regions. Top: Two brain regions (frontal cortex, FrCor; hippocampus,
Hip), the lung and liver, were collected from naïve mice (n= 6). Expression of two transcripts for each DO is presented to illustrate tissue and brain region
specificity. The sample type with the lowest expression was set to 1.0, with other samples showing relative expression levels within transcript (i.e., across row,
Ct values for FrCor are shown to illustrate relative amplification across transcripts). The tissue with the highest relative expression for each transcript is
highlighted for emphasis. Total DO expression (Ido1-Tot, Ido2-Tot, and Tdo2-Tot) was assessed using assays that span exons conserved across all transcripts
within each gene. Bottom: Similarly, brain regions were collected to quantify differences in expression levels across additional brain
regions of naïve mice (n = 4). Expression within the frontal cortex was set to 1.0 for all transcripts, and other regions show expression
relative to the FrCor. Ct values for each transcript (a: Ido1-FL, b: Ido1-v1, c: Ido1-Tot, d: Ido2-FL, e: Ido2-v1, f: Ido2-Tot, g: Tdo2-FL/v1, h: Tdo2-v1,
I: Tdo2-Tot) within the FrCor are shown to indicate relative amplification level during the qPCR reaction (Ido1-FL is essentially absent in the naïve
mouse brain; samples without a calculated Ct value are assigned a value of 40 for presentation). For both data sets, mice (10- to 12-week old) were
euthanized under CO2 and then perfused with cold saline to minimize blood content within samples prior to tissue or brain region excision. Samples
were then processed for qPCR analysis as described in the “Methods” section for OHSC samples
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systems and other in vitro models are intact. These
confirmatory data were then used to investigate the
interaction between corticosteroids and inflammatory
mediators on the expression of genes within the
Kynurenine Pathway.
Dex, Cort, and Aldo interact with IFNγ to induce Ido1
expression
In control OHSCs, Ido1-FL was essentially absent
(Ct values ≥37), but Ido1-v1 was detectible (Ct ≤ 34), a
finding that closely mimics relative expression found in
Fig. 3 Within OHSCs, Dex elicits a prototypical anti-inflammatory action and acts to down-regulate its own action. OHSCs were treated with three
inflammatory mediators (IFNγ, LPS, or pI:C) ± Dex. Gene expression of cytokines (TNFα (a) and IL-6 (b)), a chemokine (Ccl5 (c)), inducible nitric oxide
synthase 2 (iNOS, Nos2 (d)), glucocorticoid receptor (GR; Nr3c1 (e)), mineralocorticoid receptor (MR; Nr3c2 (f)), and FK506 binding protein 5 (fkbp5;
FKBP51 (g)) and 4 (fkbp4; FKBP52 (h)) was quantified as were protein levels for TNFα and IL-6 in conditioned media (inset). Expression levels are relative
to control (no inflammatory mediator and no corticosteroid) samples normalized to 1.0. *p≤ 0.05 for the main effect of an inflammatory mediator,
ϕp≤ 0.05 for the main effect of Dex; δp≤ 0.05 post hoc analysis for an interaction effect for Dex within inflammatory mediator
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brains of naïve mice (Fig. 2) validating the use of OHSCs
as a model to quantify Ido1 expression. As we have previ-
ously shown [49], IFNγ induced Ido1-FL expression
(Fig. 4a, c, and e). IFNγ also induced Ido1-v1 (Fig. 4b, d,
and f) in OHSCs, although the fold increase was not as
large as for Ido1-FL. Alone, neither Dex (A, B), Cort
(C, D), nor Aldo (E, F) changed Ido1-FL or Ido1-v1 expres-
sion. Interestingly, there was a significant interaction of
Dex with inflammatory mediators on Ido1-FL (F(3,22) = 8.1,
MSE = 6,120, p < 0.001) and Ido1-v1 expression (F(3,22) =
15.0, MSE = 130.0, p < 0.001). By post hoc analysis, Dex sig-
nificantly accentuated the ability of IFNγ to induce expres-
sion of Ido1-FL (p < 0.001) and Ido1-v1 (p < 0.001).
Although Cort and Aldo mimicked this Dex by IFNγ inter-
action, neither reached significance for Ido1-FL. However,
there were significant interactions between Cort (p < 0.001)
and Aldo (p < 0.05) with IFNγ on Ido1-v1 expression. Both
steroids significantly accentuated the ability of IFNγ to in-
duce expression of Ido1-v1. LPS and pI:C did not induce
Ido1-FL or Ido1-v1 expression, nor did they interact with
Cort, Dex, or Aldo. Collectively, these data suggest a
unique regulatory pattern for Ido1 expression. Unlike
cytokines whose expression is diminished by Dex and
Cort, Ido1-FL transcript expression is accentuated by
corticosteroids via GR activation, i.e., by Dex and
Cort. Unlike iNOS whose expression is increased only
by Dex via the GR, Ido1-v1 expression is increased
by Dex, Cort, and Aldo, suggesting mediation by the
GR, GR/MR, and MR, respectively.
Inflammatory mediators and Aldo induce Ido2 transcripts
Ido2-FL was essentially absent (Ct values ≥37) in OHSCs
and was not inducible by inflammatory mediators, corti-
costeroids, or their combination (not shown). In contrast,
Fig. 4 Two distinct Ido1 transcripts are expressed by hippocampal slice cultures, with IFNγ being a strong inducer of Ido1 expression and synergistic
with corticosteroids. OHSCs were treated with IFNγ, LPS, and pI:C ± Dex, Cort, or Aldo. Expression levels of two Ido1 transcripts (a, c, e: Ido1-FL; b, d, f:
Ido1-v1) are relative to control samples normalized to 1.0. *p≤ 0.05 for the main effect of an inflammatory mediator, ϕp≤ 0.05 for the main effect of
either Dex, Cort, or Aldo; δp≤ 0.05 post hoc analysis for an interaction effect for Dex, Cort, or Aldo within inflammatory mediator
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Ido2-v1 (Ct~32), Ido2-v2 (Ct~33), and Ido2-v3 (Ct~33)
were all detectable in OHSCs. The lower Ct of Ido2-v1
compared to Ido2-FL of OHSCs agrees with the relative
Ct levels in the hippocampus of naïve mice (Fig. 2) validat-
ing the use of OHSCs as a model to quantify Ido2 expres-
sion. Ido2-v1 (Fig. 5a, d, and g), Ido2-v2 (Fig. 5b, e, and g),
and Ido2-v3 (Fig. 5c, g, and i) expression was induced
by IFNγ (p < 0.001), with the fold induction of Ido2-v1
(~12-fold) and Ido2-v3 (~10-fold) being greater than
that for Ido2-v2 (~threefold). In contrast to Ido1 ex-
pression, LPS and pI:C induce Ido2-v1 (p < 0.001) and
Ido2-v3 (p < 0.001) expression, but like Ido1, they do
not increase Ido2-v2 expression. Interestingly, Dex did
not significantly change Ido2 expression, although there
was a significant interaction between Cort and inflam-
matory mediators for Ido2-v3 expression (F(3,23) = 5.6,
MSE = 24.4, p < 0.01). By post hoc analysis, Cort signifi-
cantly accentuated the induction of Ido2-v3 in the pres-
ence of IFNγ (p < 0.001). Cort did not alter LPS nor
pI:C action. There was neither a Cort (A, B, C) nor Dex
(D, E, F) main effect nor a significant interaction between
either Cort or Dex and inflammatory mediators for Ido2-
v1 and Ido2-v2. However, there was a small but significant
main stimulatory effect of Aldo on Ido2-v1 expression
(Fig. 5g) (p < 0.05). Thus, although there was not a signifi-
cant interaction between Aldo and inflammatory media-
tors, MR activation may enhance Ido2-v1 expression.
These data suggest that the regulation of Ido2 expression
is distinct from Ido1. Ido2 does not appear to be respon-
sive to GR activation, although MR activation has a mild
stimulatory effect that is highly dependent upon the tran-
script being assessed. Importantly, the three Ido2 tran-
scripts detected in OHSCs are differentially regulated by
IFNγ, LPS, and pI:C. This later finding illustrates again
that qPCR assay design will affect the response elicited in
a treatment-dependent manner.
Dex and Cort induce Tdo2-FL expression
A few studies have suggested that glucocorticoids regulate
Tdo2 expression by peripheral tissues [41, 42]; however,
corticosteroid regulation of specific Tdo2 transcripts has
not been reported. Here, we show that all three Tdo2 tran-
scripts are expressed by OHSCs with varied amplification
results; average Ct’s were ~29, ~25, and ~25 for Tdo2-FL/
v1, Tdo2-v1, and Tdo2-v2, respectively. Thus, Tdo2-v1
has a lower Ct value than Tdo2-FL/v1 in both OHSCs and
in the hippocampus of naïve mice (Fig. 2), again validating
the use of OHSCs as a model to quantify DO expression.
Addition of IFNγ, LPS, and pI:C did not alter the expres-
sion of any Tdo2 transcripts (Fig. 6a–f), but both Dex
(Fig. 6a; p < 0.001) and Cort (Fig. 6d; p ≤ 0.05) induced
Tdo2-FL/v1 expression. As Tdo2-FL/v1 expression is
shown to be highest in the hippocampus (Fig. 2), a brain
region with a high density of both GRs and MRs [51, 52],
Fig. 5 Three distinct Ido2 transcripts are expressed by hippocampal slice cultures, with IFNγ, LPS, pI:C, and Aldo inducing expression of specific
Ido2 transcripts. OHSCs were treated with IFNγ, LPS, and pI:C ± Dex, Cort, or Aldo. Expression of Ido2 transcripts (a, d, g: Ido2-v1; b, e, h: Ido2-v2;
c, f, i: Ido2-v3) are relative to control samples normalized to 1.0. *p≤ 0.05 for the main effect of an inflammatory mediator; ϕp ≤ 0.05 for the main
effect of Dex, Cort, or Aldo; δp ≤ 0.05 post hoc analysis for an interaction effect for Dex, Cort, or Aldo within inflammatory mediator
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it is not surprising that both Dex and Cort induce Tdo2-
FL. Aldo did not alter Tdo2-FL expression (not shown),
indicating that the stimulatory effects of Cort and Dex are
mediated by the GR. Surprisingly, Tdo2-v1 and Tdo2-v2
expression were not regulated by corticosteroids. Since
the assay for Tdo2-FL also amplifies Tdo2-v1, the latter
having a lower Ct and thus possible greater expression
level, the true inductive power of Cort and Dex on Tdo2-
FL expression is diluted by the concurrent detection of
the non-inducible Tdo2-v1 transcript. This finding con-
firms that the Tdo2-FL sequence is not just a truncated/
incomplete version of Tdo2-v1, but that Tdo2-FL is a
unique transcript under distinct regulatory control com-
pared to its two counterparts. These results also indicate
that quantifying corticosteroid induction of Tdo2 is only
feasible when assessing expression of the Tdo2-FL
transcript.
Changes in the genetic expression of enzymes
downstream of DOs along the Kynurenine Pathway
There are several enzymes involved in the metabolism of
tryptophan along the Kynurenine Pathway. Although the
DOs are rate limiting for entry of tryptophan into the
pathway, downstream enzymes are necessary for the
conversion of Kyn to either QuinA or KynA. Kat2, Kynu,
KMO, and Haao are involved in the conversion of Kyn
neuroactive metabolites (Fig. 7 picture insert). By analyz-
ing the expression pattern of three of these enzymes, we
further emphasize the unique transcriptional regulation
of the DOs. None of the downstream enzymes were in-
ducible by Dex, Cort, or Aldo, and none showed the
positive interaction between inflammatory mediators
and GR or MR activation. There was an inflammatory
main effect on KMO and Kynu expression in which both
LPS and pI:C significantly induced the expression of
KMO (Fig. 7a) (p < 0.01) while IFNγ and LPS signifi-
cantly increased Kynu (Fig. 7b) (p < 0.05). Dex decreased
the expression of KMO (p < 0.05) and Kynu (p < 0.001).
Haao expression was not changed by any of the treatments
nor their combination (Fig. 7c). In contrast, LPS and pI:C
significantly decreased Kat2 expression (p < 0.001), without
an effect of Dex (Fig. 7d). The actions of Dex on Kynu and
KMO expression were mimicked by Cort, but not Aldo
(not shown). These findings support the hypothesis that
corticosteroids regulate expression of KMO and Kynu en-
zymes via the GR. Overall, the stimulatory effect of inflam-
matory mediators on Kynu and KMO expression in
parallel with a decrease in Kat2 expression should shift
Kyn metabolism towards QuinA production (Fig. 7 insert).
This effect would be somewhat tempered by the inhibitory
effect of Dex on Kynu and KMO expression. More import-
antly, the non-rate limiting enzymes are not susceptible to
the positive interaction between IFNγ and corticosteroids
to induce Ido1 or the induction by Aldo or Dex seen with
Ido2 and Tdo2, respectively.
Discussion
Induction of the Kynurenine Pathway by inflammatory
stimuli or stress has been associated with the develop-
ment of depression-like behaviors [26–30, 33]. An un-
derstanding of the regulation of enzymes within this
pathway will aid in discovering the mechanism for the
etiology of inflammation-induced depression. This is the
first study to (1) design assays for specific mRNA tran-
script variants of Ido1, Ido2, and Tdo2, (2) describe tis-
sue specificity for each variant, and (3) uncover a novel
interaction between inflammatory mediators and stress
hormones to induce specific Ido1, Ido2, and Tdo2
mRNA transcript variants. OHSCs were used to model
how the hippocampus responds to corticosteroids and
Fig. 6 Three distinct Tdo2 transcripts are expressed by hippocampal slice cultures with Cort and Dex inducing only Tdo2-FL. OHSCs were treated
with IFNγ, LPS, and pI:C ± Dex or Cort. Expression levels of Tdo2 transcripts (a, d: Tdo2-FL/v1; b, e: Tdo2-v1; c, f: Tdo2-v2) are relative to control
samples normalized to 1.0. ϕp≤ 0.05 for the main effect of either Dex or Cort
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inflammatory stimuli. We validated the OHSC model by
showing that GR, but not MR, activation elicits an
anti-inflammatory response while initiating a negative
feedback loop (↓ GR, ↑ FKBP51). Thus, OHSCs maintain
corticosteroid responses that occur in the intact murine
brain. Unexpectedly, LPS- and pI:C-induced iNOS expres-
sion was accentuated by Dex. Microglial iNOS expression
is induced by LPS but attenuated by Dex [53, 54]. However,
after 6 h (as in the current study), Dex did not attenuate
the LPS-induced iNOS promoter activity in astrocytes [55].
Thus, not all cells respond with a diminution of iNOS ex-
pression. The cell type, or cell-cell interaction within
OHSCs, that mediates Dex-enhanced iNOS expression is
unknown at this time.
In contrast to the expected anti-inflammatory re-
sponse, Dex, Cort, and Aldo amplified the ability of
IFNγ to increase Ido1 expression, establishing that both
GR and MR activation are involved in the induction of
Ido1. Whether corticosteroids synergize with IFNγ to in-
duce Ido1-FL or Ido1-v1 expression by a specific cell
type(s) is unknown. Additionally, we found that OHSCs
express three Ido2 transcripts. IFNγ-induced expression
of all three transcripts whereas LPS and pI:C increased
expression of only two transcripts. Aldo and Cort, but
not Dex, upregulated the expression of specific Ido2
transcripts although these responses were muted com-
pared to that of Ido1. Aldo moderately induced expres-
sion of Ido2-v1 independent of inflammation, while Cort
interacted with IFNγ to accentuate expression of Ido2-
v3. These findings suggest a small but significant MR-
mediated regulation of Ido2. Finally, OHSCs express
three Tdo2 transcripts; Cort and Dex (not Aldo) increase
expression of only one Tdo2 transcript, indicating a GR-
mediated stimulatory response. These important data
are essential in further understanding the regulation of
the Kynurenine Pathway in the brain and detailing the
Fig. 7 Regulation of mRNA expression of enzymes downstream of the DOs in the Kynurenine Pathway in hippocampal slice culture. OHSCs were
treated with IFNγ, LPS, and pI:C ± Dex. Kynu (a), Kat2 (b), KMO (c) and Haao (d) expression was quantified relative to control samples normalized to 1.0.
*p≤ 0.05 for the main effect of an inflammatory mediator, ϕp≤ 0.05 for the main effect of Dex
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importance of investigating post-transcriptional regula-
tion of the DO genes.
Ido1 expression is induced by IFNγ in human and
mouse microglia, macrophages, astrocytes [56–60], neu-
rons [61], brain endothelial cells [62], and mouse OHSCs
([45]; Fig. 4). However, although extremely critical to our
understanding of DO regulation, none of these manu-
scripts provide enough information to determine basal
expression or to identify variations in transcript(s) re-
sponsiveness to IFNγ. In the current work and as
suggested in the literature, Ido1-FL mRNA expression
is extremely low to undetectable in the naïve mouse
brain (Fig. 2) [63, 64], including the hippocampus
[65]. Although there is essentially no Ido1-FL mRNA
in the naïve mouse brain, there is Ido1 enzymatic activity
[66–68]. Enzymatic activity attributed to Ido1 in the naïve
must derive from the protein product of Ido1-v1.
Similarly, we have shown that control OHSCs have
Ido1 enzymatic activity [30]; OHSCs express Ido1-v1
but not Ido1-FL (Fig. 3). As such, basal Ido1 activity
within OHSCs (like naïve mouse brain) must be mediated
by the Ido1-v1-encoded protein. Confirmation of this con-
clusion awaits overexpression of this variant and assess-
ment of its activity. Austin [44] overexpressed a ~51 kDa
Ido1-FL protein, whereas Ball [24] and Pallotta [45]
overexpressed ~45 kDa proteins. Whether the enzymatic
activity of the smaller proteins was due to Ido1-FL- or
Ido1-v1-derived product or whether the two products
have similar specific activities was unclear.
We find Ido1-v1 in all brain regions examined (Fig. 2)
with particular enrichment in the striatum and hypothal-
amus. The relevance of this finding relative to animal
behavior, especially relative to inflammation- and stress-
induced depression-like behavior and innate immune re-
sponses in the CNS, warrants further investigation. To
determine the human relevance of DO transcript regula-
tion, we have generated assays to measure human Ido1,
Ido2, and Tdo2 variant transcripts. We detected multiple
Ido1, Ido2, and Tdo2 transcripts (unpublished data) in
human cells. Several Ido1 and Ido2 transcripts were
IFNγ inducible and further induced by corticosteroids.
This work suggests that the complex regulation of DO
transcripts that we have identified in the mouse hippocam-
pus is also present in human cells. Relevance of these find-
ing to psychiatric diseases warrants further investigation.
Glucocorticoid response elements (GRE) modulate GR
and MR binding to promoters to directly affect gene
transcription. Using Motif Map, we found no evidence
for a GRE within the mouse Ido1 or Ido2 genes. This
finding suggests that corticosteroid:receptor complexes
(C:GR or C:MR) are not binding directly to the Ido1 or
Ido2 promoter but are more likely to interact with the
IFNγ signaling cascade to accentuate Ido1 and Ido2 ex-
pression. IFNγ activates the Janus kinase/signal transducer
and activator of transcription (JAK/STAT) pathway, and
C:GR’s can enhance JAK/STAT signaling to increase gene
transcription independent of GREs [69–73]. These pub-
lished mechanisms suggest that GR activation (by Dex or
Cort) enhance Ido1-FL, Ido1-v1, Ido2-v3, and iNOS ex-
pression via JAK/STAT. To date, the C:MR complex has
not been shown to directly modulate the JAK/STAT path-
way although we did find that Aldo interacts with IFNγ to
induce Ido1-v1 expression. The mechanism by which
Aldo and IFNγ interact to induce Ido1-v1 or Aldo acts in-
dependently to induce Ido2-v1 expression is unclear at
this time. Independent of the mechanism, our findings are
important because they illustrate a multifaceted inter-
action between corticosteroids and IFNγ to upregulate
genes along the Kynurenine Pathway, particularly the rate-
limiting enzymes Ido1 and Ido2.
Ido2-FL mRNA has been reported as low to undetect-
able in the naïve mouse brain [24, 64]. However, in a
separate study using a probe that detects all Ido2 tran-
scripts, Ido2 mRNA was detected in neurons of the
cerebral cortex and cerebellum [74]. Using qPCR, we
find Ido2-FL primarily in the mouse striatum and hypo-
thalamus, whereas Ido2-v1 is expressed uniformly across
at least four brain regions (Fig. 2). Only variant Ido2
transcripts were detectable in OHSCs. Unlike Ido1, Ido2
transcripts are induced by LPS and pI:C, in addition to
IFNγ. Also, Ido2-v1 expression is increased by Aldo
alone. However, similar to Ido1, Ido2-v2 was induced
only by IFNγ. Thus, it is clear that Ido2 is regulated in a
transcript-specific manner by both inflammatory media-
tors and corticosteroids.
Proteins encoded by Ido2-FL and Ido2-v3 are enzy-
matically active although the Ido2-FL product has higher
activity/unit protein than the variant protein encoded by
Ido2-v3 [47]. This result suggests that differential ex-
pression of Ido2 transcripts will have profound effects
on net enzymatic activity. Thus, it is critical to evaluate
expression of all transcripts and ultimately the enzymatic
activity of each protein variant. Clearly an assay such as the
one that quantifies all three Ido2 transcripts (Ido2-Tot)
does not accurately reflect changes in expression of any
given variant (Fig. 2), nor would it be expected to parallel
enzymatic activity.
The presence of a significant LPS and pI:C effect on
Ido2 expression may relate to an undiscovered role for
Ido2 during bacterial and viral infections within the
brain. The induction of Ido1 and Ido2 transcripts by
IFNγ within OHSCs mimics the cytokine-mediated re-
sponse of the brain to a peripheral infection. This induc-
tion is critical to the development of depression-like
behaviors [28, 35]. However, based upon data in this re-
port, it is quite possible that specific Ido2 transcripts will
be induced by bacterial (e.g., LPS) or viral (e.g., pI:C) in-
fection within the brain. To date, there are no studies
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describing behavioral responses associated with the in-
duction of Ido2, due to lack of Ido2-specific inhibitors
and only the recent development of Ido2KO mice [47].
Thus, the role of Ido2 in inflammation-dependent psy-
chiatric diseases is unknown.
Tdo2 mRNA is present throughout the rodent brain
[48, 75]. Similar to the study by Kanai [48], our results
suggest that there are unique and unappreciated roles
for the various Tdo2 transcripts within the brain. Tdo2-
FL and Tdo2-v1 encode the same mature protein, while
Tdo2-v2 encodes an N-terminal truncated “variant” pro-
tein. Both Tdo2 protein isoforms have similar enzymatic
activity [48]. Since any qPCR assay designed to quantify
Tdo2-FL also assays Tdo2-v1, it is impossible to inde-
pendently assess Tdo2-FL expression. However, Tdo2-FL
is not a simple incomplete sequence of Tdo2-v1 but is
rather a unique transcript that is controlled by specific
regulatory mechanisms. As supported by our OHSCs
data, the expression of only Tdo2-FL is induced by Dex
and Cort. This inductive response is probably a direct ef-
fect of Dex and Cort on GR activation as a GRE motif
has been predicted within the Tdo2 gene [76, 77].
There is a significant amount of research suggesting
that elevated Ido1 and Ido2 is associated depression-like
behavior [28, 35] and elevated Tdo2 expression is linked
to Schizophrenia [78, 79]. With very minimal information
on the activity of the proteins translated from variant DO
transcripts, the results presented in this manuscript are
only the first step of many necessary to define their role in
depression or other psychiatric diseases. Although it is
generally believed that DO enzymatic activity within the
brain of naïve and experimental mice [66–68] results from
the protein product of Ido1-FL, our data suggest that the
expression of other DO variants may be responsible for
Kyn production within the brain. Ascertaining the enzym-
atic activity of each transcript product is outside the scope
of this study, but such knowledge would greatly add to the
understanding of the functional relevance of the DOs and
their relevance to psychiatric diseases.
Conclusions
In conclusion, our data support a role of the Kynurenine
Pathway in major depression [80] and suggest that in-
flammatory and corticosteroid pathways converge to in-
duce DO expression. This convergence has not been
previously tested. Our data show that Ido1, Ido2, and
Tdo2 are differentially regulated (summarized in Fig. 7e).
Ido1 induction by IFNγ is enhanced by GR and MR acti-
vation, suggesting that stress hormones interact with
IFNγ to enhance kynurenine synthesis within the hippo-
campus. In contrast, Ido2 transcripts are activated by
IFNγ, LPS, and pI:C. Thus, Ido2 expression is responsive
to peripheral immune-cell-derived IFNγ (resident cells
in the brain do not produce IFNγ) and bacterial or viral
infections (via LPS or dsRNA) but relatively unaffected
by stress hormones. Finally, Tdo2 transcripts are either
unchanged (v1 and v2) or induced by GR activation
(Tdo2-FL) indicating a unique stress responsiveness. As-
sociating physiological and behavioral consequences to
the differential regulation of DO transcripts is beyond
the scope of this manuscript. However, these data show
that rate-limiting enzymes for tryptophan metabolism
along the Kynurenine Pathway can be differentially regu-
lated to allow the brain to specifically respond to various
challenges. Quantifying the expression of a single DO or
a single DO transcript will not accurately reflect the true
expression of the tryptophan-degrading enzymes. Thus,
it is imperative to evaluate the expression of each tran-
script for both animal and in vitro studies. The current
study validated assays that are needed to achieve this
goal. It is also the first work to describe Ido1, Ido2, and
Tdo2 variant transcripts within the brain.
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